HRP20180527T1 - Modulatori receptora sfingozin 1-fosfata i postupci kiralne sintheze - Google Patents
Modulatori receptora sfingozin 1-fosfata i postupci kiralne sintheze Download PDFInfo
- Publication number
- HRP20180527T1 HRP20180527T1 HRP20180527TT HRP20180527T HRP20180527T1 HR P20180527 T1 HRP20180527 T1 HR P20180527T1 HR P20180527T T HRP20180527T T HR P20180527TT HR P20180527 T HRP20180527 T HR P20180527T HR P20180527 T1 HRP20180527 T1 HR P20180527T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- residue
- compound
- tetrahydronaphthalene
- alkyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 12
- 230000015572 biosynthetic process Effects 0.000 title claims 3
- 238000003786 synthesis reaction Methods 0.000 title claims 3
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 23
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 239000012069 chiral reagent Substances 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- -1 cyclobutynyl Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 claims 1
- JRCCMJGRDJTQNS-UHFFFAOYSA-N 1-azido-1,2,3,4-tetrahydronaphthalene Chemical compound C1=CC=C2C(N=[N+]=[N-])CCCC2=C1 JRCCMJGRDJTQNS-UHFFFAOYSA-N 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Claims (14)
1. Spoj sa strukturnom Formulom I-R ili I-S, ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat:
[image]
[image]
,
naznačen time što
X je -NR′R′′ ili -OR′′′;
Y je -CN, -Cl, -CF3, I, -COOH, ili -COOR1;
R′ je H, C1-4 alkil, n-hidroksi C1-4 alkil, -SO2-R1 ili -CO-R1;
R′′ je H, -SO2-R3, C1-4 alkil, koji može biti supstituiran s 1 ili više R2, ili prstenasti ostatak, koji može biti supstituiran s R4, gdje je takav prstenasti ostatak piperidinil, cikloheksil, morfolinil, tiazolil, pirazolil, pirolidinil, imidazolil ili fenil;
ili R′ i R′′, uzeti zajedno s atom dušika na kojeg su vezani, tvore 4, 5 ili 6-eročlani zasićeni heterociklički prsten, koji sadrži 0 ili 1 dodatni heteroatom, gdje je takav dodatni heteroatom O ili N, gdje takav heterocikl može biti jednostruko ili višestruko supstituiran supstituentima koje se neovisno bira iz skupine koju čine -OH, okso, - NH2, n-hidroksi-C1-4 alkil, -COOH, -(CH2)m-COOH, -(CH2)m-COOR1, -N(R1R1), te -(CH2)m-CO-N(R5R5);
R′′′ je H, C1-4 alkil ili -CO-R1;
svaki R1 je neovisno C1-4 alkil ili H;
svaki R2 je neovisno H, halogen, OH, okso, =NH, NH2, -COOH, F, -NHR1, -N(R5R5), -SO2-R1, -SO2-N(R5R5), -N(R1)-SO2-R1, -COOR1, -OCO-R1, -CO-N(R5R5), -N(R1)-COR1, C1-3 alkil, C1-3 alkoksi, i prstenasti ostatak, koji može biti supstituiran s R4, gdje je takav prstenasti ostatak piperazinil, piperidinil, morfolinil, pirolidinil, pirazolil, imidazolil, benzimidazolil, azetidinil, ciklobutinil ili fenil;
svaki R3 je neovisno R2, C1-4 alkil, C3-6 cikloalkil ili C1-4 alkil, koji može biti supstituiran s 1 ili više R2;
svaki R4 je neovisno halogen, OH, -NH2, -NHR1, -N(R1R1), -COOH, -COOR1, -NHCO-R1;
svaki R5 je neovisno C1-4 alkil ili H, ili dva R5, uzeta zajedno s atom dušika na kojeg su vezani, tvore 4, 5 ili 6-eročlani zasićeni heterociklički prsten, koji sadrži 0 ili 1 dodatni heteroatom, gdje je takav dodatni heteroatom O ili N, gdje takav heterocikl može biti supstituiran s -OH, -NH2, -N(R1R1), n-hidroksi C1-4 alkilom, -(CH2)m-COOH, -(CH2)m-COOR1; i
svaki m je neovisno 0, 1, 2 ili 3.
2. Spoj u skladu s patentnim zahtjevima 1, naznačen time što je spoj uglavnom enantiomerno čist.
3. Spoj u skladu s patentnim zahtjevima 1-2, naznačen time što je X -NR′R′′.
4. Spoj u skladu s patentnim zahtjevima 1-2, naznačen time što se spoj bira između spojeva 1-55:
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
i
[image]
,
ili njegova farmaceutski prihvatljiva sol, hidrat ili solvat.
5. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-4.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-4, ili pripravak u skladu s patentnim zahtjevom 5, naznačeni time što su namijenjeni upotrebi u liječenju multiple skleroze, odbacivanja presatka, sindroma akutnog respiratornog distresa, ulceroznog kolitisa, influence, Crohnove bolesti ili sindroma respiratornog distresa kod odraslih.
7. Postupak sinteze spoja Formule I-R ili I-S u skladu s patentnim zahtjevima 1-4, koji sadrži tetrahidronaftalenski ostatak, koji ima kiralni ugljik u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka, gdje je spoj enantiomerno obogaćen u odnosu na kiralni ugljik, naznačen time što se postupak sastoji u koracima
(i) osiguravanja spoja koji sadrži tetrahidronaftalenski ostatak, gdje je ugljik u prstenu šesteročlanog zasićenog prstena tetrahidronaftalenskog ostatka na kojem se želi postići kiralnu supstituciju okso supstituiran na takvom ugljiku;
(ii) reakcije takvog spoja s kiralnim reagensom kako bi se dobilo kiralni centar na ugljiku u tetrahidronaftalenskom ostatku, prethodno vezan na skupinu okso.
8. Postupak u skladu s patentnim zahtjevom 7, naznačen time što se spoj koji sadrži tetrahidronaftalenski ostatak dobiven u koraku (i) stavlja u kontakt s kiralnim reagensom kako bi se u koraku (ii) dobilo Formulu VI-R ili VI-S:
[image]
[image]
,
gdje je Z -CN, -Cl ili -CF3.
9. Postupak u skladu s patentnim zahtjevom 8, naznačen time što postupak dodatno uključuje korak reverzije kiralne konfiguracije na kiralnom ugljiku u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka prethodno vezanom na skupinu okso obradom Formule VI-R ili VI-S difenilfosforil-azidom (DPPA) kako bi se dobilo azidotetrahidronaftalen Formule VII-S ili VII-R:
[image]
[image]
,
gdje supstituent azido u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka zamjenjuje supstituent hidroksi, a kiralni ugljik vezan na supstituent azido ima obratnu kiralnu konfiguraciju na kiralnom ugljiku u odnosu na kada je bio prethodno vezan na hidroksi supstituent.
10. Postupak u skladu s patentnim zahtjevom 9, naznačen time što je Z -CN, a postupak dodatno uključuje korak dobivanja supstituiranog 1,2,4-oksadiazola na tetrahidronaftalenskom ostatku
(a) reakcijom međuprodukta VII-R ili VII-S sa zaštitnim sredstvom, te reakcijom dobivenog zaštićenog oblika međuprodukta VII-R ili VII-S s hidroksilaminom ili hidroksilamin-hidrokloridom kako bi se dobilo hidroksiamidin na fenilnom ugljiku na kojeg je Z vezan, gdje spoj dobiven takvom reakcijom ima Formulu VIII-R ili VIII-S:
[image]
[image]
i
(b) stavljanjem u kontakt međuprodukta Formule VIII-R ili VIII-S sa supstituiranom benzojevom kiselinom i konjugacijskim reagensom kako bi se dobilo spoj Formule IX-R ili IX-S:
[image]
[image]
,
gdje je X OH, N3, NH-PG, NH2 ili NR′R′′; PG je zaštitna skupina; R′ je H, C1-4 alkil, n-hidroksi C1-4 alkil, -SO2-R1 ili -CO-R1; R′′ je H, -SO2-R3, C1-4 alkil, koji može biti supstituiran s 1 ili više R2, ili prstenasti ostatak, koji može biti supstituiran s R4, gdje je takav prstenasti ostatak piperidinil, cikloheksil, morfolinil, tiazolil, pirazolil, pirolidinil, imidazolil ili fenil; Ra je niži alkil, a R1, R2, R3, te R4 su definirani kao u patentnom zahtjevu 1.
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time što spoj Formule IX-R ili IX-S ima strukture prikazane niže:
[image]
[image]
.
12. Postupak u skladu s patentnim zahtjevima 7-11, naznačen time što je dobiveni spoj koji sadrži tetrahidronaftalenski ostatak, koji ima kiralni ugljik u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka, enantiomerno obogaćen najmjanje 90%.
13. Spoj, naznačen time što ga se bira iz skupine koju čine:
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
.
14. Postupak sinteze spoja Formule I-R ili I-S u skladu s patentnim zahtjevom 1, koji sadrži tetrahidronaftalenski ostatak, koji ima kiralni ugljik u šesteročlanom zasićenom prstenu tetrahidronaftalenskog ostatka, gdje je spoj enantiomerno obogaćen u odnosu na kiralni ugljik, naznačen time što se postupak sastoji u koracima
(i) osiguravanja spoja koji sadrži tetrahidronaftalenski ostatak, gdje je ugljik u prstenu šesteročlanog zasićenog prstena tetrahidronaftalenskog ostatka na kojem se želi postići kiralnu supstituciju okso supstituiran na takvom ugljiku;
(ii) reakcije takvog spoja s kiralnim reagensom kako bi se dobilo kiralni centar na ugljiku u tetrahidronaftalenskom ostatku, prethodno vezan na skupinu okso.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26128209P | 2009-11-13 | 2009-11-13 | |
US26247409P | 2009-11-18 | 2009-11-18 | |
EP10830877.6A EP2498611B1 (en) | 2009-11-13 | 2010-11-15 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
PCT/US2010/056757 WO2011060389A1 (en) | 2009-11-13 | 2010-11-15 | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20180527T1 true HRP20180527T1 (hr) | 2018-05-04 |
Family
ID=43992104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180527TT HRP20180527T1 (hr) | 2009-11-13 | 2018-03-29 | Modulatori receptora sfingozin 1-fosfata i postupci kiralne sintheze |
Country Status (24)
Country | Link |
---|---|
US (3) | US8357706B2 (hr) |
EP (1) | EP2498611B1 (hr) |
JP (1) | JP5988379B2 (hr) |
KR (1) | KR101781233B1 (hr) |
CN (1) | CN102724880B (hr) |
AU (1) | AU2010320041B2 (hr) |
BR (1) | BR112012011430A8 (hr) |
CA (1) | CA2780433C (hr) |
CY (1) | CY1120427T1 (hr) |
DK (1) | DK2498611T3 (hr) |
EA (1) | EA023183B1 (hr) |
ES (1) | ES2665461T3 (hr) |
HR (1) | HRP20180527T1 (hr) |
HU (1) | HUE036391T2 (hr) |
IL (1) | IL219690B (hr) |
LT (1) | LT2498611T (hr) |
MX (1) | MX2012005562A (hr) |
MY (1) | MY160907A (hr) |
NZ (1) | NZ599913A (hr) |
PL (1) | PL2498611T3 (hr) |
PT (1) | PT2498611T (hr) |
RS (1) | RS57070B1 (hr) |
SI (1) | SI2498611T1 (hr) |
WO (1) | WO2011060389A1 (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3406142T3 (pl) * | 2009-11-13 | 2021-08-30 | Receptos Llc | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej |
CN102724880B (zh) | 2009-11-13 | 2016-09-14 | 瑞塞普托斯有限责任公司 | 1-磷酸鞘氨醇受体调节剂及手性合成方法 |
EP2706999B1 (en) * | 2011-05-13 | 2019-08-28 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
CN103251950B (zh) * | 2012-02-16 | 2018-10-02 | 中国人民解放军军事科学院军事医学研究院辐射医学研究所 | S1p受体调节剂防治肠型放射病及放射性肠炎的用途 |
JP6267221B2 (ja) * | 2012-11-16 | 2018-01-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 2−トリフルオロメチルイソニコチン酸及びエステルの調製方法 |
KR101939657B1 (ko) | 2013-02-20 | 2019-01-17 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물 |
US20170165236A1 (en) * | 2013-11-01 | 2017-06-15 | Celgene International Ii Sàrl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
HUE060594T2 (hu) | 2015-11-13 | 2023-03-28 | Oppilan Pharma Ltd | Heterociklusos vegyületek betegség kezelésére |
TW201730148A (zh) * | 2015-12-22 | 2017-09-01 | 艾伯維德國有限兩合公司 | 作為s1p調節劑的稠合(雜)環化合物 |
EP3448519A4 (en) * | 2016-04-29 | 2020-01-22 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
US11192886B2 (en) * | 2016-07-22 | 2021-12-07 | Medshine Discovery Inc. | S1P1 agonist and application thereof |
CN106749213B (zh) * | 2016-11-25 | 2019-07-02 | 济南大学 | 一种具有1,2,4-恶二唑结构的吲哚衍生物及制备方法和在制备抗菌药物中的应用 |
CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
CN108727292A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 一种奥扎莫德及其中间体的制备方法 |
AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
CN110256288A (zh) * | 2019-05-13 | 2019-09-20 | 苏州山青竹生物医药有限公司 | 一种制备(s)-1-氨基-2,3-二氢-1h-茚-4-甲腈的方法 |
CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
JPWO2021157682A1 (hr) | 2020-02-06 | 2021-08-12 | ||
EP4116295A4 (en) | 2020-03-04 | 2023-08-02 | Helioeast Pharmaceutical Co., Ltd. | TRICYCLIC COMPOUNDS AND THEIR USE |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
FR2628103B1 (fr) | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
WO1992018462A1 (en) | 1991-04-12 | 1992-10-29 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
GB2290790A (en) * | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
ATE249455T1 (de) * | 1998-01-23 | 2003-09-15 | Sankyo Co | Spiropiperidin-derivate |
US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
JP4516430B2 (ja) * | 2002-12-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | 1−(アミノ)インダン並びに(1,2−ジヒドロ−3−アミノ)−ベンゾフラン、ベンゾチオフェン及びインドール |
BRPI0409319B8 (pt) | 2003-04-11 | 2021-05-25 | Ptc Therapeutics Inc | composto, composição farmacêutica, forma de dosagem unitária, e, uso de um composto |
CA2539438A1 (en) * | 2003-10-01 | 2005-04-14 | Merck And Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
JP2008531546A (ja) * | 2005-02-22 | 2008-08-14 | テバ ファーマシューティカル インダストリーズ リミティド | エナンチオマー性インダニルアミン誘導体の合成のための改良されたプロセス |
KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
EP1963509A4 (en) * | 2005-12-21 | 2009-07-29 | Joseph Gabriele | CATECHOLAMINE-REGULATED PROTEIN |
JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | H3受容体のテトラリン拮抗薬 |
US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
MX2009006304A (es) * | 2006-12-15 | 2009-06-23 | Abbott Lab | Nuevos compuestos de oxadiazol. |
WO2008143730A2 (en) | 2007-02-28 | 2008-11-27 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
WO2009131090A1 (ja) | 2008-04-21 | 2009-10-29 | 旭化成ファーマ株式会社 | アミノ酸化合物 |
EA021672B1 (ru) | 2008-05-14 | 2015-08-31 | Дзе Скриппс Рисёч Инститьют | Модуляторы рецепторов сфингозин-1-фосфата и их применение |
WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
CN102724880B (zh) | 2009-11-13 | 2016-09-14 | 瑞塞普托斯有限责任公司 | 1-磷酸鞘氨醇受体调节剂及手性合成方法 |
MX2012005559A (es) | 2009-11-13 | 2012-08-23 | Receptos Inc | Moduladores heterociclicos selectivos del receptor de esfingosina 1 fosfato. |
PL3406142T3 (pl) * | 2009-11-13 | 2021-08-30 | Receptos Llc | Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej |
WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2010
- 2010-11-15 CN CN201080061143.3A patent/CN102724880B/zh active Active
- 2010-11-15 DK DK10830877.6T patent/DK2498611T3/en active
- 2010-11-15 NZ NZ599913A patent/NZ599913A/en unknown
- 2010-11-15 AU AU2010320041A patent/AU2010320041B2/en active Active
- 2010-11-15 RS RS20180389A patent/RS57070B1/sr unknown
- 2010-11-15 CA CA2780433A patent/CA2780433C/en active Active
- 2010-11-15 MX MX2012005562A patent/MX2012005562A/es active IP Right Grant
- 2010-11-15 LT LTEP10830877.6T patent/LT2498611T/lt unknown
- 2010-11-15 ES ES10830877.6T patent/ES2665461T3/es active Active
- 2010-11-15 JP JP2012539063A patent/JP5988379B2/ja active Active
- 2010-11-15 US US12/946,800 patent/US8357706B2/en active Active
- 2010-11-15 EA EA201290331A patent/EA023183B1/ru not_active IP Right Cessation
- 2010-11-15 WO PCT/US2010/056757 patent/WO2011060389A1/en active Application Filing
- 2010-11-15 EP EP10830877.6A patent/EP2498611B1/en active Active
- 2010-11-15 PL PL10830877T patent/PL2498611T3/pl unknown
- 2010-11-15 KR KR1020127015219A patent/KR101781233B1/ko active IP Right Grant
- 2010-11-15 HU HUE10830877A patent/HUE036391T2/hu unknown
- 2010-11-15 MY MYPI2012002085A patent/MY160907A/en unknown
- 2010-11-15 SI SI201031665T patent/SI2498611T1/en unknown
- 2010-11-15 PT PT108308776T patent/PT2498611T/pt unknown
- 2010-11-15 BR BR112012011430A patent/BR112012011430A8/pt not_active Application Discontinuation
-
2012
- 2012-05-09 IL IL219690A patent/IL219690B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,669 patent/US20130196966A1/en not_active Abandoned
-
2015
- 2015-02-27 US US14/634,439 patent/US9394264B2/en active Active
-
2018
- 2018-03-29 HR HRP20180527TT patent/HRP20180527T1/hr unknown
- 2018-04-04 CY CY20181100376T patent/CY1120427T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180527T1 (hr) | Modulatori receptora sfingozin 1-fosfata i postupci kiralne sintheze | |
ES2929376T3 (es) | Nuevos compuestos | |
ES2360222T3 (es) | Agentes policíclicos para el tratamiento de infecciones respiratorias por virus sincicial. | |
AU2023201775A1 (en) | Compounds, compositions and methods | |
ES2314460T3 (es) | Compuestos de 2,3-dihidro-6-nitroimidazo (2,1-b)oxazol para el tratamiento de la tuberculosis. | |
ES2609578T3 (es) | Amino-quinolinas como inhibidores de quinasa | |
ES2305038T3 (es) | Composiciones farmaceuticas para cns y otros trastornos. | |
ES2397389T3 (es) | Derivados de piridilo y su uso como agentes terapéuticos | |
ES2444777T3 (es) | Compuestos de nicotinamida útiles como moduladores de quinasas | |
BR112020014151A2 (pt) | Compostos de benzamida | |
ES2941818T3 (es) | Quinazolinonas como inhibidores de PARP14 | |
AR045536A1 (es) | Inhibidores de la fosfodiesterasa tipo -iv | |
ES2675799T3 (es) | Moduladores selectivos del receptor esfingosina 1-fosfato heterocíclica | |
ES2411880T3 (es) | Usos terapéuticos de derivados de quinazolinodiona | |
BR112012023576A2 (pt) | compostos anti-infecciosos | |
HRP20211728T1 (hr) | Rsv antivirusni pirazolo- i triazolo-pirimidinski spojevi | |
AU2013276520A1 (en) | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents | |
ES2644758T3 (es) | Moduladores de PKM2 y métodos para su uso | |
HRP20170337T1 (hr) | N-(4-(azaindazol-6-il)-fenil)-sulfonamidi i njihova uporaba kao farmaceutska sredstva | |
ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
ES2897998T3 (es) | Inhibidores de la acilsulfonamida del NaV1.7 | |
SA07280728B1 (ar) | مشتقات بنزوثيازولون وتركيبات صيدلانية تشتمل عليها | |
AR065333A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
HRP20180480T1 (hr) | Piridazinoni kao inhibitori daao enzima | |
AU2021277619B2 (en) | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |